comprehensive -WSS

comprehensive

author：focus 2025-09-30 19:26:22 - browse：75

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The tragedy of Johnson & Johnson’s Covid vaccine

WSS

FDA clears AI tool for detecting skin cancer

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Obesity drug from Roche shows promise in early study

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

CVS is willing to dump 10% of its Medicare Advantage members

Supreme Court to hear if Covid misinformation is protected speech

focus

comprehensive

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

NIH director takes cautious approach to Biden drug pricing priority

Medicare details structure of new drug price negotiation program

Readout Newsletter: Merck, J&J, and long Covid

Jerome Adams on the need for new antivirals for Covid

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

What does generative AI mean for health care? We asked experts

ALS treatment from Biogen, Ionis fails in study

Tori Bowie and the unacceptable rates of Black maternal death

Copay coupons to count toward deductibles, after Biden court move

explore

Research misconduct: Proposed new rules face resistance

NIH director takes cautious approach to Biden drug pricing priority

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

WuXi Biologics beefs up its lobbying operation

Think you might have Covid

Galapagos to make CAR

leisure time

hotspot

focus

explore